Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -40,7 +40,7 @@
40	40	* 1new molecular entity approval
41	41
42	42
43		-[[image:AZN2.png]]
	43	+[[image:AZN4.png||alt="AZN2.png"]]
44	44
45	45
46	46	=== Cambridge ===
...	...	@@ -67,36 +67,34 @@
67	67	Looking to the future, Gothenburg has initiated the creation of a new, global cluster for health and life sciences, as part of the GoCo Health Innovation City project, which includes the Gothenburg BioVentureHub. There are currently more than 30 external companies and one academic group co-locating with AstraZeneca at the heart of the Gothenburg site. By facilitating interactions between drug, device, diagnostics and digital health companies, AstraZeneca is creating a dynamic, creative and fertile environment for helping unlock the power of what science can do.
68	68
69	69
	70	+[[image:AZN2.png]]
70	70
	72	+
71	71	= Therapy Area =
72	72
73	73	== Oncology ==
74	74
75		-AstraZeneca has a bold ambition to provide cures for cancer in every form. AstraZeneca is following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
	77	+AstraZeneca has a bold ambition to provide cures for cancer in every form. AstraZeneca is following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.{{footnote}}https://www.astrazeneca.com/our-therapy-areas/oncology.html{{/footnote}}
76	76
77		-[[https:~~/~~/www.astrazeneca.com/our-therapy-areas/oncology.html>>url:https://www.astrazeneca.com/our-therapy-areas/oncology.html]]
78	78
79	79	The company's Oncology strategy is built with one goal in mind – to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer. The company's broad pipeline of next-generation medicines, together with its focus on excellence in execution, are aimed at expanding treatment options and improving outcomes for patients with solid tumours and haematological cancers.
80	80
81	81	The company focus on four strategic priorities:
82	82
83		-•Pioneering research across six scientific platforms: Tumour drivers and resistance; Immuno-oncology; DNA damage response, Antibody drug conjugates, Epigenetics and Cell therapies
	84	+* Pioneering research across six scientific platforms: Tumour drivers and resistance; Immuno-oncology; DNA damage response, Antibody drug conjugates, Epigenetics and Cell therapies
	85	+* Advancing innovative clinical strategies to treat early stages of disease and relapsed or refractory patients
	86	+* Building expertise and leadership in the most prevalent and highest mortality rate tumour types
	87	+* Delivering across its global footprint
84	84
85		-•Advancing innovative clinical strategies to treat early stages of disease and relapsed or refractory patients
86	86
87		-•Building expertise and leadership in the most prevalent and highest mortality rate tumour types
	90	+**key disease areas**
88	88
89		-•Delivering across its global footprint
90		-
91		-key disease areas
92		-
93	93	The company's focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, the company hope to achieve life-changing benefits for patients.
94	94
95		-BioPharmaceuticals
96	96
97		-Through its work in BioPharmaceuticals, the company want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. There remains a huge unmet need in treating people with chronic diseases. The company's ambition is to stop the progress of these often degenerative, debilitating, and life-threatening  conditions, achieve remission, and one day cure them.
	95	+== BioPharmaceuticals ==
98	98
99		-[[https:~~/~~/www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html>>url:https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html]]
	97	+Through its work in BioPharmaceuticals, the company want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. There remains a huge unmet need in treating people with chronic diseases. The company's ambition is to stop the progress of these often degenerative, debilitating, and life-threatening  conditions, achieve remission, and one day cure them.{{footnote}}https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html{{/footnote}}
100	100
101	101
102	102	BioPharmaceuticals is responsible for its key therapy areas of Cardiovascular, Renal & Metabolism and Respiratory & Immunology.
...	...	@@ -107,16 +107,16 @@
107	107
108	108	The company will achieve its ambition of transforming healthcare through its talented teams and partners using scientific, medical and commercial innovation.
109	109
110		-BioPharmaceuticals Business Unit
111	111
	109	+**BioPharmaceuticals Business Unit**
	110	+
112	112	The company's commercial teams are transforming how the company bring products to market; engage with patients, healthcare providers and health systems; and deliver healthcare solutions that support them.
113	113
114	114
115		-Cardiovascular, Renal and Metabolism
	114	+== Cardiovascular, Renal and Metabolism ==
116	116
117		-The company aim to save the lives of people who suffer from cardiovascular disease, heart failure, chronic kidney disease and diabetes, by advancing CVRM solutions and addressing shared risk factors between these distinct but interrelated disease areas
	116	+The company aim to save the lives of people who suffer from cardiovascular disease, heart failure, chronic kidney disease and diabetes, by advancing CVRM solutions and addressing shared risk factors between these distinct but interrelated disease areas{{footnote}}https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html{{/footnote}}
118	118
119		-[[https:~~/~~/www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html>>url:https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html]]
120	120
121	121	Cardiovascular, Renal & Metabolism (CVRM) diseases are the leading causes of death across the globe, killing more than 20 million people each year.
122	122